FAK Inhibitors
2 drugsAbout FAK
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase involved in cell adhesion, migration, proliferation, and survival signaling pathways. Its role in these processes has made it a target for drug development, especially in oncology.
FAK's involvement in tumor growth and metastasis supports its therapeutic potential, despite the lack of direct genetic evidence linking it to specific diseases. Targeting FAK may disrupt cancer progression.
Two FDA-approved drugs target FAK: LORBRENA and AVMAPKI FAKZYNJA CO-PACK (COPACKAGED), both small molecules used in oncology. These drugs highlight FAK inhibition as a therapeutic strategy.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Low Grade Serous Ovarian Cancer with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Drugs
Pfizer and VERASTEM INC are the companies with approved FAK-targeting drugs.
Limited competition suggests an opportunity for new entrants, but high barriers to entry exist.
Drug Modality Landscape
Modalities
Routes of Administration
FAK is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
Clinical Trials 78 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 25 | 16 | 3 | 6 | 84% |
| Phase 2 | 31 | 5 | 5 | 21 | 50% |
| Phase 3 | 10 | 4 | 0 | 6 | 100% |
| Phase 4 | 12 | 6 | 1 | 5 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2018 - 2025)
The first FAK-targeting drug was approved in 2018, with the most recent in 2025.
Recent approval indicates continued interest, but monitor for market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 66 clinical trials targeting FAK.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities